Boehringer provides update on iclepertin Phase III program in schizophrenia
16 janv. 2025 10h05 HE
|
Boehringer Ingelheim Limited
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were...
Online Therapy Service for Teenagers Market Experiences Robust Growth, Surpassing $80 Billion in 2024, Driven by Innovative Online Therapy Models and Increased Awareness - Long-term Forecast to 2033
03 janv. 2025 06h39 HE
|
Research and Markets
Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The "Online Therapy Service for Teenagers Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The online therapy service market...
Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
17 déc. 2024 06h00 HE
|
Kynexis
KYN-5356, an innovative, first-in-class small molecule inhibitor of KAT-II, a key enzyme in the kynurenine pathway implicated in schizophrenia, was shown to be safe and well-tolerated in the phase 1...
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
05 nov. 2024 07h30 HE
|
Minerva Neurosciences, Inc
Minerva Neurosciences (Nasdaq: NERV) today reported business updates and financial results for the third quarter of 2024 ending September 30, 2024.
Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight
09 oct. 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight The rise in research and development activities in...
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
06 août 2024 07h30 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases
29 mai 2024 07h00 HE
|
Kynexis
NAARDEN, The Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain...
The BC Schizophrenia Society Calls on British Columbians to #StandAgainstStigma this National Schizophrenia and Psychosis Awareness Day
24 mai 2024 10h00 HE
|
BC Schizophrenia Society
VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- The British Columbia Schizophrenia Society (BCSS), a provincial non-profit organization dedicated to supporting individuals and families...
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
01 mai 2024 07h30 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
16 avr. 2024 02h30 HE
|
Nxera Pharma
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine BiosciencesSuccessful completion of...